Skip to main content
SpringerLink
Log in

Hepatitis B

  • Published:
Wiener klinische Wochenschrift Education

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Perz JF, Armstrong GL, Farrington LA, et al (2006) The contributions of hepatitis B virus and hepatitis C virus infection to cirrhosis and primary liver cancer worldwide. J Hepatol 45: 529–538

    Article  PubMed  Google Scholar 

  • World Health Organisation (2002) Hepatitis B. Electronic Citation. www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf

  • Epidemiologisches Bulletin 49/ 2007, Robert Koch Institut

  • Ganem D, Prince AM (2004) Hepatits B Virus Infection – Natural History and Clinical Consequences. N Engl J Med 350: 1118–1129

    Article  PubMed  CAS  Google Scholar 

  • Petersen J. www.hepatitisandmore.de/archiv/2007-1

  • Scheiblauer H, Soboll H, Nick S (2006) Evaluation of 17-CE marked HBsAg-assays with respect clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol 78 [Suppl 1]: 66–70

    Article  Google Scholar 

  • Cornberg M, et al (2007) Prophylaxe, Diagnostik und Therapie der HBV Infektion. Z Gastroenterol 45: 1–50

    Google Scholar 

  • Pawlotsky JM (2002) Molecular diagnosis of viral hepatitis. Gastroenterology 122: 1554–1568

    Article  PubMed  CAS  Google Scholar 

  • Han Y, Tang Q, Zhu W, et al (2008) Clinical, biochemical, immunological and virological profiles of, and differential diagnosis between, patients with acute hepatitis B and chronic hepatitis B with acute flare. J Gastroenterol Hepatol 23: 1728–1733

    Article  PubMed  Google Scholar 

  • Hadziyannis SJ, Papatheodoridis GV (2006) Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liv Dis 26: 130–141

    Article  CAS  Google Scholar 

  • Impfplan Österreich. Evidenz-basierte Empfehlungen des Obersten Sanitätsrates 06-11-2007

  • Miyake Y (2008) Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med 47: 1293–1299

    Article  PubMed  Google Scholar 

  • Chen CJ, Yang HI, Su J, et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65–73

    Article  PubMed  CAS  Google Scholar 

  • EASL International consensus conference on hepatitis B. 13–14 September, 2002, Geneva, Switzerland (2003) Consensus statement. The EASL Jury. J Hepatol 39: 3–25

    Google Scholar 

  • Craxì A, Di Bona D, Cammà C (2003) Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol 39 [Suppl 1]: 99–105

    Article  Google Scholar 

  • Fattovich G, Brollo L, Boscaro S, et al (1989) Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B. J Hepatol 9: 331–337

    Article  PubMed  CAS  Google Scholar 

  • Korenman J, Baker B, Waggoner J, et al (1991) Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 114: 629–634

    PubMed  CAS  Google Scholar 

  • Lin SM, Yu ML, Lee CM, et al (2007) Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46: 45–52

    Article  PubMed  CAS  Google Scholar 

  • Cooksley WG, Piratvisuth T, Lee SD, et al (2003) Peginterferon alpha-2a (40kDa): an advance in the treatment of hepatitis B. J Viral Hepat 10: 298–305

    Article  PubMed  CAS  Google Scholar 

  • Marcellin P, Lau GK, Bonino F, et al (2004) Peginterferon alpha-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351: 1206–1217

    Article  PubMed  CAS  Google Scholar 

  • Janssen HL, van Zonneveld M, Senturk H, et al (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365: 123–129

    Article  PubMed  CAS  Google Scholar 

  • Locarnini S, Hatzakis A, Heathcote J, et al (2004) Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 9: 679–693

    PubMed  CAS  Google Scholar 

  • Chang TT, Gish RG, de Man R, et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001–1010

    Article  PubMed  CAS  Google Scholar 

  • Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al (2003) Adefovir Dipivoxil 438 Study Group. Adefovir Dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348: 800–807

    Article  PubMed  CAS  Google Scholar 

  • Liaw YF, Sung JJ, Chow WC, et al (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521–1531

    Article  PubMed  CAS  Google Scholar 

  • Dienstag JL, Schiff ER, Wright TL, et al (1999) Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341: 1256–1263

    Article  PubMed  CAS  Google Scholar 

  • Hoofnagle JH, Doo E, Liang TJ, et al (2007) Management of hepatitis B: Summary of a clinical research workshop. Hepatology 45: 1056–1075

    Article  PubMed  CAS  Google Scholar 

  • Peters MG, Hann HW, Martin P, et al (2004) Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126: 91–101

    Article  PubMed  CAS  Google Scholar 

  • Marcellin P, Heathcote EJ, Buti M, et al (2008) Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B. N Engl J Med 359: 2442–2455

    Article  PubMed  CAS  Google Scholar 

  • van Bömmel F, Zöllner B, Sarrazin C, et al (2006) Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44: 318–325

    Article  PubMed  Google Scholar 

  • Lai CL, Leung N, Teo EK, et al (2005) A 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis B e antigene-positivs chronic hepatitis B. Gastroenterology 129: 528–536

    PubMed  CAS  Google Scholar 

  • Chan HL, Heathcote EJ, Marcellin P, et al (2007) Treatment of hepatitis B e antigene positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 147: 745–754

    PubMed  Google Scholar 

  • Lai CL, Rosmawati M, Lao J, et al (2002) Entecavir is superior to lamuvudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123: 1831–1838

    Article  PubMed  CAS  Google Scholar 

  • Chang TT, Gish RG, Hadziyannis SJ, et al (2005) A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129: 1198–1209

    Article  PubMed  CAS  Google Scholar 

  • Colonno R, Rose R, Baldick C, et al (2005) Entecavir two year resistance update: no resistance observed in nucleoside-naïve patients and low frequency resistance emergence in lamivudine refractory patients. Hepatology 42 [Suppl 1]: 573–574

    Google Scholar 

  • Lee HS, Chung YH, Lee K, et al (2006) A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic Hepatitis B. Hepatology 43: 982–988

    Article  PubMed  CAS  Google Scholar 

  • Keeffe EB, Zeuzem S, Koff RS, et al (2007) Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 5: 890–897

    Article  PubMed  Google Scholar 

  • Di Marco V, Marzano A, Lampertico P, et al (2004) Clinical outcome of HBe-Ag-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40: 883–891

    Article  PubMed  CAS  Google Scholar 

  • Samuel D, Muller R, Alexander G, et al (1993) Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329: 1842–1847

    Article  PubMed  CAS  Google Scholar 

  • Stärkel P, Stoffel M, Lerut J, et al (2005) Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected HBV-infected liver graft recipients. Liver Transpl 11: 1228–1234

    Article  PubMed  Google Scholar 

  • Lok AS, McMahon BJ (2007) AASLD Practice Guidelines: chronic hepatitis B. Hepatology 45: 507–539

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinik für Innere Medizin II, Gastroenterologie und Hepatologie, Medizinische Universität Innsbruck, Innsbruck, Austria

    Susanne Abbrederis & Wolfgang Vogel

Authors
  1. Susanne Abbrederis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Vogel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanne Abbrederis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abbrederis, S., Vogel, W. Hepatitis B. Wiener Klin. Wochenschr. Educ. 4, 43–55 (2009). https://doi.org/10.1007/s11812-009-0051-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11812-009-0051-y

Search

Navigation